目的 分析銀杏酮酯分散片對腦卒中患者血清炎癥因子水平、神經(jīng)功能改善情況。方法 本研究對象選取92例腦卒中患者，按照隨機數(shù)字表法分成對照組和觀察組各46例。對照組患者給予常規(guī)治療，觀察組患者在此基礎(chǔ)上輔以銀杏酮酯分散片口服治療。連續(xù)治療14 d，對比兩組治療前后血清炎癥因子水平、血脂水平、神經(jīng)功能缺損程度、認(rèn)知功能、不良反應(yīng)的差異。結(jié)果 治療前兩組患者血清白介素-8（IL-8）、白介素-6（IL-6）、腫瘤壞死因子-α（TNF-α）水平無統(tǒng)計學(xué)差異；治療后兩組IL-8、IL-6、TNF-α水平均明顯降低，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；且觀察組血清IL-8、IL-6、TNF-α水平低于對照組，組間有顯著的統(tǒng)計學(xué)差異（P<0.05）。治療前兩組患者血脂水平無統(tǒng)計學(xué)差異；治療后對照組TC明顯降低，HDL-C明顯升高，差異有統(tǒng)計學(xué)意義（P<0.05）；觀察組TG、TC、LDL-C低于對照組，HDL-C高于對照組，組間差異有統(tǒng)計學(xué)意義（P<0.05）。治療前兩組患者NIHSS評分、MMSE評分無統(tǒng)計學(xué)差異；治療后兩組NIHSS評分均降低，MMSE評分均升高，同組治療前后比較差異有統(tǒng)計學(xué)意義（P<0.05）；觀察組NIHSS評分低于對照組、MMSE評分高于對照組，組間差異有統(tǒng)計學(xué)意義（P<0.05）。治療期間兩組均未見不良反應(yīng)報告。結(jié)論 銀杏酮酯分散片可降低腦卒中患者血清中促炎癥因子水平、調(diào)節(jié)血脂水平、減輕神經(jīng)功能缺損程度、改善認(rèn)知功能，且無明顯不良反應(yīng)，值得臨床推廣應(yīng)用。

Objective To analyze the serum levels of inflammatory factors and neurological function in patients with stroke treated with Ginkgo biloba extract dispersible tablets.Methods 92 stroke patients were randomly divided into the control group and the observation group, with 46 cases in each group. Patients in the control group were given conventional treatment, and the observation group was treated with Ginkgo acetate dispersible tablets on the basis of oral treatment. The serum levels of inflammatory factors, blood lipid levels, neurological impairment, cognitive function and adverse reactions were compared between the two groups before and after treatment with 14 d.Results Before treatment, two groups of patients with serum IL-8, IL-6 and TNF-levels had no significant difference; after treatment, serum IL-8, IL-6, TNF-levels lower than the control group, there was a significant difference between the groups (P < 0.05). There was no significant difference in serum lipid level between the two groups before treatment. After treatment, the TG, TC and LDL-C in the observation group were lower than that in the control group, and HDL-C was higher than that in the control group, and there was a statistically significant difference between the two groups (P < 0.05). Two groups of patients with NIHSS score and MMSE score had no significant difference before treatment; after treatment, NIHSS score of observation group was lower than that of the control group, MMSE score higher than the control group, there was a significant difference between the groups (P < 0.05). There were no adverse reactions in the two groups during the treatment.Conclusion Ginkgo biloba dispersible tablets can reduce the level of inflammatory factors, regulating blood lipid level, reduce the degree of neurological deficit, improve cognitive function of patients with stroke in serum, and no obvious adverse reactions, it is worthy of clinical application.